{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:48:12Z","timestamp":1794937692765,"version":"4.9.1"},"reference-count":26,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Clonal hematopoiesis (CH) is more common in older persons and has been associated with an increased risk of hematological cancers and cardiovascular diseases. The most common CH mutations occur in the DNMT3A and TET2 genes and result in increased proinflammatory signaling. The Canakinumab Anti-inflammatory Thrombosis Outcome Study (NCT01327846) evaluated the neutralizing anti-IL1\u03b2 antibody canakinumab in 10,061 randomized patients with a history of myocardial infarction and persistent inflammation; DNA samples were available from 3,923 patients for targeted genomic sequencing. We examined the incidence of non-hematological malignancy by treatment assignment and CH mutations and estimated the cumulative incidence of malignancy events during trial follow-up. Patients with TET2 mutations treated with canakinumab had the lowest incidence of non-hematological malignancy across cancer types. The cumulative incidence of at least one reported malignancy was lower for patients with TET2 mutations treated with canakinumab versus those treated with placebo. These findings support a potential role for canakinumab in cancer prevention and provide evidence of IL1\u03b2 blockade cooperating with CH mutations to modify the disease course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Prevention Relevance:<\/jats:title>\n                    <jats:p>We reveal that administering canakinumab is associated with a decrease in non-hematological malignancies among patients with clonal hematopoiesis (CH) mutations. These findings underscore canakinumab\u2019s potential in preventing cancer and provide proof of IL1\u03b2 blockade collaborating with CH mutations to enhance its clinical benefits.<\/jats:p>\n                    <jats:p>Watch the interview with Tingting Zhai, PhD, recipient of the 2025 Cancer Prevention Research Award for Outstanding Journal Article: https:\/\/vimeo.com\/1100471597<\/jats:p>\n                    <jats:p>See related Spotlight, p. 399<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1940-6207.capr-23-0342","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T16:44:59Z","timestamp":1714754699000},"page":"429-436","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial"],"prefix":"10.1158","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9617-4301","authenticated-orcid":false,"given":"Janghee","family":"Woo","sequence":"first","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4317-9924","authenticated-orcid":false,"given":"Tingting","family":"Zhai","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7006-2885","authenticated-orcid":false,"given":"Fang","family":"Yang","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0161-3506","authenticated-orcid":false,"given":"Huilei","family":"Xu","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-6571","authenticated-orcid":false,"given":"Margaret L.","family":"Healey","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-515X","authenticated-orcid":false,"given":"Denise P.","family":"Yates","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-0005","authenticated-orcid":false,"given":"Michael T.","family":"Beste","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5130-9284","authenticated-orcid":false,"given":"David P.","family":"Steensma","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"2026042015293710500_bib1","first-page":"1606","article-title":"Clonal hematopoiesis and nonhematologic disorders","volume":"136","author":"Jaiswal","year":"2020","journal-title":"Blood"},{"key":"2026042015293710500_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"2026042015293710500_bib3","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"2026042015293710500_bib4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"2026042015293710500_bib5","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2026042015293710500_bib6","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"2026042015293710500_bib7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2026042015293710500_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCRESAHA.120.317104","article-title":"Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure","volume":"128","author":"Abplanalp","year":"2021","journal-title":"Circ Res"},{"key":"2026042015293710500_bib9","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/2159-8290.CD-22-0086","article-title":"Distinct tumor necrosis factor alpha receptors dictate stem cell fitness versus lineage output in Dnmt3a-mutant clonal hematopoiesis","volume":"12","author":"SanMiguel","year":"2022","journal-title":"Cancer Discov"},{"key":"2026042015293710500_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u03b2\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026042015293710500_bib11","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-022-01121-z","article-title":"Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis","volume":"54","author":"Kar","year":"2022","journal-title":"Nat Genet"},{"key":"2026042015293710500_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-022-05448-9","article-title":"Common and rare variant associations with clonal haematopoiesis phenotypes","volume":"612","author":"Kessler","year":"2022","journal-title":"Nature"},{"key":"2026042015293710500_bib13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.22.00857","article-title":"Clonal hematopoiesis and risk of incident lung cancer","volume":"41","author":"Tian","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026042015293710500_bib14","article-title":"United States Food and Drug Administration","author":"Ilaris (canakinumab) FDA PI"},{"key":"2026042015293710500_bib15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026042015293710500_bib16","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"2026042015293710500_bib17","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-19-3176","article-title":"Inhibition of IL1\u03b2 by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial","volume":"80","author":"Wong","year":"2020","journal-title":"Cancer Res"},{"key":"2026042015293710500_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026042015293710500_bib19","first-page":"2214","article-title":"A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets","volume":"141","author":"Vlasschaert","year":"2023","journal-title":"Blood"},{"key":"2026042015293710500_bib20","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1182\/bloodadvances.2023011578","article-title":"Effects of IL-1\u03b2 inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial","volume":"7","author":"Woo","year":"2023","journal-title":"Blood Adv"},{"key":"2026042015293710500_bib21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N Engl J Med"},{"key":"2026042015293710500_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"key":"2026042015293710500_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"2026042015293710500_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10555-006-9004-4","article-title":"The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions","volume":"25","author":"Apte","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"2026042015293710500_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"2026042015293710500_bib26","doi-asserted-by":"crossref","first-page":"155850","DOI":"10.1016\/j.cyto.2022.155850","article-title":"Interleukin-1 (IL-1) and the inflammasome in cancer","volume":"153","author":"Pretre","year":"2022","journal-title":"Cytokine"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/doi\/10.1158\/1940-6207.CAPR-23-0342\/3451288\/capr-23-0342.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/doi\/10.1158\/1940-6207.CAPR-23-0342\/3461414\/capr-23-0342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/17\/9\/429\/3485600\/capr-23-0342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/17\/9\/429\/3485600\/capr-23-0342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:29:48Z","timestamp":1776713388000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/17\/9\/429\/747009\/Effect-of-Clonal-Hematopoiesis-Mutations-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,3]]},"published-print":{"date-parts":[[2024,9,4]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-23-0342","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1940-6207.26934472.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29636059","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29619082","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934469.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29619070","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934466.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934475.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934481.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934478","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29619076","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934472","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934466","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29636071","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29636065","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29636068","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29619073","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934469","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29619079","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29619067","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934481","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934475","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.26934478.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29636062","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.29636074","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1940-6207.c.7431502.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.7431502","asserted-by":"object"}]},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]}}}